RE:AstraZeneca's ADC disappoints - on severe adverse events"Clinical data so far have unexpectedly shown that ADCs fail to increase their payloads’ maximum tolerated dose, as previously thought.80 Indeed, a thorough elucidation of ADC mechanisms of action, as well as their PK and PD profiles, is largely lacking, warranting for the introduction of more reliable in vivo and in vitro models. In addition, research and innovations in the field of ADC design are also greatly envisaged. In particular, future developments may involve the use of bispecific, or tumorspecific antigen-targeting, mAbs, or novel payloads with immune-stimulatory/radioactive molecules, or the use of dual payloads within the same construct."
https://www.esmoopen.com/article/S2059-7029(23)00843-8/pdf